Auranofin*

New oral gold compound for treatment of rheumatoid arthritis

A. E. FINKELSTEIN†, D. T. WALZ, V. BATISTA, M. MIZRAJI, F. ROisman, and A. MISHER

From the Smith Kline & French Laboratories, Philadelphia, Pa., and the Institute of Clinical Pharmacology and Experimental Therapeutics, Buenos Aires, Argentina—Montevideo, Uruguay

Finkelstein, A. E., Walz, D. T., Batista, V., Mizraji, M., Roisman, F., and Misher, A. (1976). Annals of the Rheumatic Diseases, 35, 251–257. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Eight patients with rheumatoid arthritis were treated with SK&F D-39162 (auranofin), a new oral gold compound which was effective in suppressing adjuvant-induced arthritis in rats. Clinical and humoral parameters were studied during a 3-month period of drug administration followed by a 3-month period under placebo. The drug was absorbed, well tolerated, and its action was manifested by a drop in the mean IgG blood levels in the third week of treatment accompanied by clinical improvement after 5 weeks of oral gold intake. Together with IgG changes, an increase of the albumin ratio was observed, as well as a decrease of α2-globulin and rheumatoid factor titres. From a total number of 60 swollen joints found initially in the 8 patients only 17 were swollen at week 12 and 9 at week 15. Although the number of patients treated was too small to allow definite conclusions, a follow-up study under placebo of clinical and laboratory changes in the same patients during another 3-month period showed that IgG serum levels rapidly reverted preceding a flare up of disease activity after withdrawal of the drug. This confirmed a direct role in cause-effect relation played by the new oral gold compound.

The Empire Rheumatism Council (1960), after a controlled study, confirmed the effectiveness of gold salts treatment for rheumatoid arthritis (RA). This was established, however, 30 years after Forestier’s (1929) publication on gold therapy in chronic rheumatism. Furthermore, the Cooperating Clinics Committee of the American Rheumatism Association (1973), in a double-blind controlled study of gold salts therapy in 68 patients with clinical RA, confirmed the conclusions of the Empire Rheumatism Council with regard to the beneficial effects of gold treatment in RA.

Recently, Sigler and others (1974), in a 2-year double-blind study of the effects of gold salts in 27 RA patients, reported clinical improvement; and a radiological follow-up study showed that bone and cartilage destruction was arrested in several patients, the mean progression rate of destruction being significantly slowed for the gold-treated group. Gold compounds are, therefore, capable of successfully altering not only the clinical but also the radiological course of rheumatoid disease activity. The mechanism by which this is achieved is still unknown, and sequential studies of humoral changes during and after gold treatment are not available in the literature reviewed.

Recently, Sutton and others (1972) described a series of gold compounds in which the gold was complexed with trialkylphosphines, that exhibited antiarthritic activity after oral administration to adjuvant arthritic rats. SK&F D-39162 (auranofin), one of the most active compounds in this series, was further evaluated by Walz and others (1973, 1976) in a variety of in vivo and in vitro test procedures and found to possess a unique pharmacological profile in

Accepted for publication November 21, 1975.

* SK&F D-39162 (2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranosato-S) (triethylphosphine) gold.

† Director, Institute of Clinical Pharmacology and Experimental Therapeutics, Buenos Aires-Montevideo.

†† Correspondence to Dr. Donald T. Walz, Smith Kline & French Laboratories, 1500 Spring Garden Street, Philadelphia, Pa. 19101, U.S.A.
that it inhibited antibody production, lysosomal enzyme release from phagocytosing leucocytes, and mediator release in immediate hypersensitivity reactions.

This report describes the use of SK&F D-39162 in RA, its effect on disease activity, and a follow-up of sequential changes in humoral and clinical parameters which occurred during a 6-month period of evaluation: 3 months under oral gold compound treatment followed by 3 months on placebo.

Materials and methods

CLINICAL MATERIAL

Two groups of 4 patients each were studied, all having a clinical diagnosis of rheumatoid arthritis according to ARA criteria (Ropes and others, 1958). They were selected as being free from cardiovascular, renal, hepatic, and gastrointestinal diseases. None had been under immunosuppressive or gold treatment. Only one patient (Case 3) had previously received steroid therapy which was discontinued one month before gold was administered. Table I gives clinical and laboratory findings in the 8 RA patients. The stage and class of the patients follows Steinbrocker’s criteria (Steinbrocker, Traeger, and Batterner, 1949).

ORAL GOLD ADMINISTRATION

Group I received SK&F D-39162 orally in the form of 3 mg capsules twice a day during 3 months; group II received 3 mg twice a day during the first 3 weeks, followed by 3 mg three times a day until completion of the 12-week treatment. Each capsule of 3 mg of gold compound is equivalent to 0.87 mg of gold. Therefore, group I received a total gold dose of 12.18 mg weekly in daily oral doses; group II received the same quantity during the first 3 weeks followed by 0.87 mg of gold three times a day, a total weekly intake of 18.27 mg of gold. Placebo was given during the 3-month follow-up study. In no case did the patients know that the drug was discontinued after the first 3-month period. No patient withdrew from the study. 2 patients from group I (Cases 1 and 2) and 2 patients from group II (Cases 7 and 8) were hospitalized; the others were followed as outpatients. Hospitalized patients were seen by two physicians daily. Ambulatory patients were clinically controlled when they returned for laboratory determinations. The rheumatologist recorded symptoms and pertinent physical findings, with special attention to the morning stiffness period, and the number of swollen joints in each patient. Fasting blood specimens were drawn from each patient and urine samples were collected for the following laboratory studies: complete blood count (haemoglobin, haematocrit, white blood count, differential), platelets, ESR, urinalysis, blood urea nitrogen, creatinine, uric acid, total bilirubin, SGOT, SGPT, lactic dehydrogenase, alkaline phosphatase, serum glucose, Na, Cl, K, CO₂, creatinine clearance, and stools for occult blood. These studies were done at weeks 0, 1, 2, 3, 5, 7, 9, and 12, and continued in a similar sequence during the following 3 months on placebo. Blood and urine samples were taken twice weekly for gold determination by atomic absorption spectroscopy according to Lorber and others (1968). Serum protein electrophoresis was done on acetic cellulose gel and IgG, IgM, IgA determination by radial immunodiffusion (Mancini, Carbonara, and Heremans, 1965), using Hyland plates. Rheumatoid factor titres were determined according to Singer and Plotz (1956).

IN VIVO BINDING DISTRIBUTION STUDIES OF SK&F D-39162 TO SERUM PROTEIN FRACTION IN RA

Preparative electrophoresis on cellophane block, 0.25 x 6 x 17 cm, were carried out with 0.5 ml of serum (Case 7) at week

<table>
<thead>
<tr>
<th>Table I</th>
<th>Changes of clinical and laboratory parameters during and after treatment with SK&amp;F D-39162</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case No.</td>
<td>Sex</td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
</tr>
<tr>
<td>Group I</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
</tr>
<tr>
<td>Group II</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>F</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
</tr>
</tbody>
</table>

* Steinbrocker and others (1949).
† Reciprocal titres.

Total number of swollen joints: week 1: 60, week 12: 17.
12 under oral SK&F D-39162 treatment. 140 V were applied during a 4-hour running period, using a TRIS-barbituric buffer (10-30 g sodium diethylbarbiturate; 1-84 g diethylbarbituric acid; and 7-2 g TRIS in 1-0 l distilled water). Serum fraction positions were determined and impressed on a celloidry film, then the fractions were cut with a razor blade and eluted. Protein determinations of the eluted fractions were performed according to Lowry's method (Lowry and others, 1951) and gold levels of each fraction were estimated by neutron activation analysis.

Results

BLOOD AND URINE GOLD LEVELS

The oral gold compound was well absorbed by the 8 patients during the first 3 months of treatment. Fig. 1 shows curves obtained with the mean blood gold levels of groups I and II. In the third week, when group II increased the oral gold intake to 3 mg t.i.d., a rise of blood gold concentration took place. There is no evidence of a 'steady state' or 'plateau' in either group. A straight line of increased blood gold levels in function of time is clearly shown.

Similar ascendant curves were obtained with the mean values of 24-hour urinary gold excretion in function of time in both groups of RA patients. The correlation of mean values of blood gold levels with mean values of 24-hour urinary gold excretion in both groups of patients is shown in Fig. 2. The correlation between blood and urine gold levels was studied by the least square statistical method, and the patients in group I showed a correlation coefficient of $0.8663$ (highly significant, $P < 0.001$) and a regression coefficient of $0.37 \mu g/ml$ per each $100 \mu g/24$ h urinary gold excreted. Group II showed similar results: correlation coefficient $0.7972$ (highly significant, $P < 0.001$), and a regression coefficient of $0.36 \mu g/ml$ per each $100 \mu g$ of gold excreted in urine.

![FIG. 1 Effect of daily oral administration of SK&F D-39162 on blood gold levels in RA patients. Group I received 3 mg twice a day during 3 months. Group II received 3 mg twice a day during the first 3 weeks, followed by 3 mg three times a day until completion of the 12-week treatment.](http://ard.bmj.com)
joints before treatment in the 8 patients. This objective evidence of decreased rheumatoid disease activity was paralleled significantly by serum protein and immunoglobulin changes.

SERUM PROTEIN AND IMMUNOGLOBULIN STUDIES
The most significant and consistent changes were observed at follow-up in the variation of the serum protein levels which occurred during and after total oral gold administration. A marked increase of serum albumin and decrease of α₂- and γ-globulin was a constant finding in the patients studied. The mean serum albumin concentration of the 8 patients before treatment was 26-7 g/l (2.67 g/l. At the end of 3 months’ treatment the mean value increased to 32-6 g/l (3.26 g/l), and at the end of the following 3 months’ treatment on placebo the mean serum albumin concentration was 36-6 g/l (3.66 g/l). Table II gives the albumin-globulin ratio values before, during, and after treatment in patients of both groups. While the increase in albumin and decrease of α₂-globulin remains stable even at the third month on placebo (Fig. 3), after gold was stopped the γ-globulin blood levels, which decreased during treatment by 26.5% at week 12, returned to

Table II Albumin-globulin ratio changes before, during, and after treatment with SK&F D-39162

<table>
<thead>
<tr>
<th>Group I</th>
<th>Week</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0.53</td>
<td>0.44</td>
<td>0.59</td>
<td>0.66</td>
<td>0.55</td>
</tr>
<tr>
<td>Treatment</td>
<td>1</td>
<td>0.55</td>
<td>0.38</td>
<td>0.54</td>
<td>0.72</td>
<td>0.55</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.57</td>
<td>0.55</td>
<td>0.64</td>
<td>0.82</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.56</td>
<td>0.61</td>
<td>0.71</td>
<td>0.93</td>
<td>0.70</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>0.78</td>
<td>0.74</td>
<td>0.82</td>
<td>0.86</td>
<td>0.80</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>0.78</td>
<td>0.80</td>
<td>0.86</td>
<td>1.15</td>
<td>0.90</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>0.83</td>
<td>0.82</td>
<td>0.77</td>
<td>1.07</td>
<td>0.87</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>0.75</td>
<td>0.99</td>
<td>0.88</td>
<td>0.92</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>0.84</td>
<td>0.55</td>
<td>0.81</td>
<td>1.15</td>
<td>0.84</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>0.83</td>
<td>0.82</td>
<td>1.14</td>
<td>1.06</td>
<td>0.96</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>1.12</td>
<td>0.84</td>
<td>0.96</td>
<td>0.89</td>
<td>0.95</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>0.93</td>
<td>0.68</td>
<td>0.84</td>
<td>0.99</td>
<td>0.86</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group II</th>
<th>Week</th>
<th>Case 5</th>
<th>Case 6</th>
<th>Case 7</th>
<th>Case 8</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0.69</td>
<td>0.60</td>
<td>0.58</td>
<td>0.68</td>
<td>0.64</td>
</tr>
<tr>
<td>Treatment</td>
<td>1</td>
<td>0.64</td>
<td>0.82</td>
<td>0.75</td>
<td>0.78</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.73</td>
<td>0.88</td>
<td>0.80</td>
<td>0.93</td>
<td>0.83</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.97</td>
<td>0.96</td>
<td>0.77</td>
<td>1.11</td>
<td>0.95</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>0.91</td>
<td>0.87</td>
<td>0.84</td>
<td>0.97</td>
<td>0.90</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>0.74</td>
<td>0.93</td>
<td>0.92</td>
<td>0.92</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>0.88</td>
<td>0.80</td>
<td>0.89</td>
<td>0.96</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>0.98</td>
<td>1.09</td>
<td>0.91</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>0.98</td>
<td>0.93</td>
<td>0.88</td>
<td>0.88</td>
<td>0.92</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>1.04</td>
<td>1.01</td>
<td>0.97</td>
<td>0.87</td>
<td>0.97</td>
</tr>
</tbody>
</table>

FIG. 3 α₂-Globulin values in four RA patients (group I) before, during, and after treatment with SK&F D-39162, which was administered orally at a dose of 3 mg twice a day. Conversion: Traditional to SI Units—α₂-globulin: 1 g/100 ml = 10 g/l

the pre-gold values at the end of the 6-month study (Fig. 4).

Statistical analysis of variance of polynomial regression of α₂-globulin and IgG was highly significant (P < 0.005). Studies between the relation of daily gold intake and decrease in IgG, according to our data, showed that daily oral administration of 6 mg of the gold compound (1.7 mg of gold) produces a decrease of 1.24 g/l (12.35 mg/100 ml) of IgG per week during the first 9 weeks of treatment.

In Table III it can be seen that from the total γ-globulin values, IgG has the most sensitive response to the gold compound. Similar results were obtained with the patients of group II. Rheumatoid factor titres dropped in all of the patients treated (Table I),

FIG. 4 γ-Globulin values in four RA patients (group I) before, during, and after treatment with SK&F D-39162, which was administered orally at a dose of 3 mg twice a day. Conversion: Traditional to SI Units—γ-globulin: 1 g/100 ml = 10 g/l
and the greater clinical and laboratory responsiveness was observed at the earliest stage of disease.

Discussion

SK&F D-39162 was well tolerated and absorbed through the gastrointestinal tract in the 8 RA patients in whom the gold levels were studied. The blood gold levels reached with daily doses of SK&F D-39162 were one-half or one-third lower than the blood gold levels reached by the classical treatment with parenteral gold. In patients treated with SK&F D-39162 the serum gold concentrations failed to correlate with the clinical course of the disease in the patients studied. Gottlieb, Smith, and Smith (1974) and Gerber and others (1972) also could not find such a correlation after chrysotherapy.

Contrary to the lack of correlation between serum blood gold levels and the 24-hour urinary gold secretion reported during parenteral gold administration (Lorber and others, 1973), in this report on oral chrysotherapy there is a greater blood gold level stability, and a direct correlation is observed between the mean values of blood gold levels and 24-hour urinary gold excretion.

Although a limited group of patients have been studied, the four stages of RA were represented, and the greatest responsiveness to the oral gold was achieved during the earliest stages of the disease. Before treatment all the patients presented the classical humoral picture of active rheumatoid arthritis, as evidenced by low albumin, high α₂-globulin, and total γ-globulin values. This electrophoretic profile started to normalize at the third week of treatment with the compound. Clinical improvement, shown by decreased duration of morning stiffness and number of swollen joints, began the fifth week of treatment.

All our rheumatoid patients presented hypo-albuminaemia (mean value 26 g/l (2.6 g/100 ml) before oral gold). The striking result after oral gold was a stable increase of 10 g/l (1 g/100 ml) average value for 8 patients, lasting even 3 months after gold was discontinued. Studies of albumin metabolism in RA (Wilkinson and others, 1965; and Ballantyne, Fleck, and Dick, 1971) showed that the intravascular, extravascular, and total body albumin contents were significantly lower than normals, and values for fractional catabolic rates were increased and did correlate with disease activity. The mechanism by which SK&F D-39162 protects the enhanced degradation of albumin in RA requires further investigation. It is important to point out that 81-8% of gold binds in vivo with the albumin fraction according to our studies with SK&F D-39162 as determined by neutron activation analysis. Mascalenas, Granda, and Freyberg (1972), using 199AuCl after exchange with gold sodium thiomalate in in vitro studies, reported that 95% of the radioactivity was associated with the albumin fraction. Further studies are necessary to confirm the existence of a higher binding affinity to the serum globulin fractions of the oral gold.

It was found at follow-up that during the 3-month placebo period after gold was stopped, when each patient became his own control, some insight was gained into role played by the compound at an immunological level. The IgG reverted on placebo (Fig. 4), after a highly significant drop (P < 0.005), to its pretreatment levels. Clinically, this was paralleled when a flare-up of disease followed the IgG reversion to the higher pre-gold levels at the third month on placebo.

Therefore, the circulating immune response is modified by the administration of SK&F D-39162, as evidenced by its effect upon the changes produced.
on the serum IgG levels, and a drop of the initial rheumatoid factor titres. Serum IgG concentration in the 8 patients studied with SK&F D-39162 were above normal values at the beginning of oral gold administration. Statistical analysis of the relation of daily gold intake and IgG serum level variation showed that a daily oral intake of 1-7 mg of gold produced a decrease of 1.24 g/l (123.5 mg/100 ml) of IgG serum concentration per week during the first nine weeks of treatment.

During the last decade it has become evident that RA is a good example of a generalized immune complex disease, in which vasculitis and tissue deposition of immunocomplexes play an important role in the rheumatoid inflammation (Carter, 1973). In the light of the accumulation of evidence suggesting the role that IgG-RF might play through the circulating immunocomplexes or their tissue deposit in rheumatoid disease (Finkielstein and others, 1961; Kunkel and others, 1961; Chodirker and Tomasi, 1963; Schrotenloher, 1966; Munthe and Natvig, 1971; Gordon and others, 1975), the effect of SK&F D-39162 upon IgG might be its most important property as an antiarthritic agent. Furthermore, based on this action, the oral gold compound might also have its place in the treatment of the hyperviscosity syndrome described in rheumatoid arthritis due to intermediate complexes formed by self association of IgG-RFs (Pope and others, 1975), and in other disorders associated with hypergamma-globulinaemia.

Finally, it is not known whether the improvement of SK&F D-39162 on the immunological parameters in RA is produced through the inhibition of immunoglobulin synthesis or to an effect of this new compound upon the triggering aetiopathological factor of the disease. In favour of this last possibility is the lowering effect that this drug exercises upon such a sensitive acute phase reactant as α2-globulin. Further studies of mechanism of action of SK&F D-39162 at a molecular level will shed more light on the pathogenesis of rheumatoid arthritis.

A study of a larger number of patients treated during longer periods is necessary to learn more about side effects and full therapeutic value of this promising new treatment for rheumatoid arthritis.

We thank Mrs. Maria Elena A. de Bouza and Miss Nillovia Giracc for their skilled technical assistance, and Dr. R. Yabo from our Department of Statistics for the Statistical Analysis; also Drs. Lola Nudelman, A. Caballero, Robert Stote, G. Ehrlich, and Mr. M. J. DiMartino for help in the selection of clinical material and/or helpful discussions.

References


MASCARENhas, B. R., GRANDA, J. L., AND FREYBERG, R. H. (1972) *Arthr. and Rheum.*, 15, 391 (Gold metabolism in patients with rheumatoid arthritis treated with gold compounds—reinvestigated)

Auranofin—New oral gold compound


A E Finkelstein, D T Walz, V Batista, M Mizraji, F Roisman and A Misher

Ann Rheum Dis 1976 35: 251-257
doi: 10.1136/ard.35.3.251

Updated information and services can be found at:
http://ard.bmj.com/content/35/3/251

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/